ABCL AbCellera Biologics Inc. Загрузка... : Бычьи и медвежьи мнения аналитиков
Загрузка графика...
Лучшие сигналы
Лента
23:50
31 авг
31 авг
Short ABCL, add near $12
Short AbCellera and press the position if it rebounds to around $12, using that level as the trigger for adding.
Выс.
13:53
28 авг
28 авг
Short ABCL targeting single digits
Short ABCL with a new position targeting single digits; detailed commentary is deferred to the next weekly, and no catalyst is specified beyond the price objective.
Сред.
18:00
26 авг
26 авг
ABCL weekly intact despite sell signals
Notes ABCL is at a technical setup after a ~120% run; two sell signals have appeared but the weekly timeframe remains intact.
Сред.
15:24
26 авг
26 авг
The author expresses hypothetical interest in biotech via ABCL after preliminary research.
The author expresses hypothetical interest in biotech via ABCL after preliminary research, but frames it as conditional rather than a current position or explicit buy call.
Низ.
14:54
26 авг
26 авг
The author notes ABCL is a biotech name many like without typical biotech concerns.
The author notes ABCL is a biotech name many like without typical biotech concerns, but expresses no personal position or directional call.
Низ.
13:28
26 авг
26 авг
The author admits to not having researched ABCL and expresses fear of biotech.
The author admits to not having researched ABCL and expresses fear of biotech, showing no directional view.
Низ.
22:40
25 авг
25 авг
ABCL seen dipping to $8-9 then rallying
Buy ABCL for an expected pullback to $8-9 before a larger rally; it is viewed as a rare quality name.
Низ.
14:13
25 авг
25 авг
Author agrees with a parent post about healthcare leadership but only lists tickers without.
Author agrees with a parent post about healthcare leadership but only lists tickers without stating a position or forward call, so they are watch items.
Низ.
14:40
23 авг
23 авг
"Hold ABCL long despite near-term resistance"
"Hold ABCL long as an existing position; the author previously cited technicals, fundamentals, and a broader thesis as a clear buying opportunity, while this reply flags near-term resistance."
Сред.
14:46
21 авг
21 авг
Author clarifies he publicly closed a prior trade to buy more ABCL and IOVA.
Author clarifies he publicly closed a prior trade to buy more ABCL and IOVA, but does not state current positions or forward direction.
Низ.
15:47
20 авг
20 авг
The author reassures a seller that they can buy back the stock later.
The author reassures a seller that they can buy back the stock later, offering comfort rather than a directional trade call.
03:38
20 авг
20 авг
Author acknowledges hearing of ABCL in reply but expresses no directional view.
Author acknowledges hearing of ABCL in reply but expresses no directional view, merely confirming awareness of the name.
Низ.
23:56
19 авг
19 авг
Author takes profits on ABCL position.
Author discloses taking profits on ABCL position to rotate capital into a higher conviction trade.
Сред.
18:25
19 авг
19 авг
Author acknowledges a biotech list with eye emojis but gives no explicit position or forward.
Author acknowledges a biotech list with eye emojis but gives no explicit position or forward call, so all tickers are indexed as watch.
Низ.
15:41
18 авг
18 авг
Author names ABCL as his favorite pick while viewing PRME and RXRX as promising but not.
Author names ABCL as his favorite pick while viewing PRME and RXRX as promising but not explicitly held, making ABCL a clear long and the others watch.
00:01
18 авг
18 авг
Long ABCL on antibody AI drug-discovery platform
Long ABCL for its AI drug-discovery platform thesis: it maps the immune system, screens millions of cells, and aims to become the operating system pharma uses to find antibody treatments.
Сред.
11:28
15 авг
15 авг
The author lists a large basket of tickers without any explicit position language.
The author lists a large basket of tickers without any explicit position language or directional thesis, so all are indexed as watch.
Низ.
21:25
14 авг
14 авг
Insider buys make ABCL bullish.
Buy ABCL; the author views the disclosed insider purchase of 46,387 shares around $10.37 by Michael Hayden as a bullish signal, favoring insider buying over the many reasons to sell.
Сред.
15:21
14 авг
14 авг
Author takes profit on overvalued ABCL.
Author took profits on their ABCL position after a 3x gain, citing current overvaluation.
Выс.
14:51
14 авг
14 авг
Profits rotated out of ABCL into IOVA
Author took profits on ABCL and rotated proceeds into IOVA; partial exit from ABCL position disclosed.
Сред.
20:04
13 авг
13 авг
Author complains their short book is underperforming while longs dominate.
Author complains their short book is underperforming while longs dominate, listing prior short candidates as context rather than fresh trade calls.
05:02
13 авг
13 авг
ABCL long on disciplined capital raise
Buy ABCL; management demonstrated capital discipline by not upsizing an oversubscribed $200M raise, and proceeds are earmarked for growth and fulfillment, signaling quality capital allocation.
Сред.
17:13
12 авг
12 авг
Questions competitive advantage of antibody discovery platform
Questions the competitive advantage of the company's antibody discovery platform compared to hundreds of peers, noting a lack of explanation from retail bulls.
Низ.
15:56
12 авг
12 авг
ABCL cult premium collapses on commoditized platform
Short ABCL as a cult-driven overvaluation built on a commoditized antibody discovery platform with no durable differentiation; even a successful FDA approval will yield disappointing launch revenues, and pipeline failures will eventually expose the stock's terminal weakness.
Сред.
12:55
12 авг
12 авг
Author dismisses ABCL's valuation as memey and notes weak Veozah sales.
Author dismisses ABCL's valuation as memey and notes weak Veozah sales, but offers no explicit short position or downside target.
10:47
12 авг
12 авг
ABCL called overvalued meme stock
Author labels AbCellera Biologics overvalued and a meme stock within a short-selling list; valuation criticism only, no specific deterioration mechanism stated.
Низ.
15:36
11 авг
11 авг
Short-term trade position, early entry noted
Author lists ABCL as a current short-term trade position with no specific catalyst articulated beyond early entry timing.
Низ.
15:09
11 авг
11 авг
Author clarifies they do not own Abcellera despite the shoutout.
Author clarifies they do not own Abcellera despite the shoutout, so no position or directional view is expressed.
Низ.
23:52
10 авг
10 авг
The author discusses using AI and social tracking to predict biotech trial results.
The author discusses using AI and social tracking to predict biotech trial results, referencing ABCL as an example of their research method rather than stating a current position or explicit trade call.
Низ.
19:40
10 авг
10 авг
AbCellera shares surged up to 41 percent after reporting positive mid-stage trial results.
AbCellera shares surged up to 41 percent after reporting positive mid-stage trial results for a hot flash treatment candidate.
Об аналитическом покрытии ABCL
Buzzberg отслеживает ABCL (AbCellera Biologics Inc.) в 14 источниках. Бычьих сигналов: 28, медвежьих: 2, от 16 аналитиков. Сентимент преимущественно бычий (31%). Всего отслеживаются 84 торговые идеи. За последние 7 дней: медвежьих: 2. Последние спикеры: seedy19tron, wliang, itschrisray.